Celldex ends eczema drug development after mid-stage trial failure
CLDX•Celldex Therapeutics will stop developing barzolvolimab for eczema after a mid-stage study failed to meet its main and key secondary goals. The study enrolled 131 patients, and the drug did not significantly reduce itching after 16 weeks.
1. Trial missed key goals
Celldex Therapeutics said it would stop developing barzolvolimab for atopic dermatitis, commonly known as eczema, after the treatment failed to meet the main and key secondary goals of a mid-stage study involving 131 patients with moderate-to-severe disease. The drug did not significantly reduce itching after 16 weeks and showed no meaningful improvement over placebo on other key measures.
2. Other studies continue
The drug reduced mast cells, but Celldex said the results suggest they are not the main driver of atopic dermatitis. The treatment was well tolerated, though its limited improvements and lack of added benefit after 32 weeks fell short of the company’s threshold for further development. Celldex will continue late-stage studies in three hive-related skin conditions and plans to seek U.S. approval for chronic spontaneous urticaria in 2027.




